Eikon Therapeutics, Inc.

Contributing Author

Recent Articles by Eikon Therapeutics, Inc.

Jul-27	Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer EIKN +11.01% GlobeNewswire
Jul-20	Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress EIKN GlobeNewswire
Jun-25	Eikon Therapeutics to Join the Russell 3000 Index EIKN EIKN +16.24% GlobeNewswire
Jun-08	Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors EIKN GlobeNewswire
May-30	Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology EIKN GlobeNewswire
May-21	Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology EIKN GlobeNewswire
May-11	Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates EIKN EIKN +15.88% GlobeNewswire
Mar-30	Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates EIKN GlobeNewswire
Feb-04	Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering EIKN GlobeNewswire